

Disclaimer :

The Competition DG makes the information provided by the notifying parties in section 1.2 of Form CO available to the public in order to increase transparency. This information has been prepared by the notifying parties under their sole responsibility, and its content in no way prejudices the view the Commission may take of the planned operation. Nor can the Commission be held responsible for any incorrect or misleading information contained therein.

COMP/M. 5247 - DAIICHI SANKYO / RANBAXY LABORATORIES

SECTION 1.2

Description of the concentration

“Daiichi Sankyo Company, Limited, Japan (“DS”), proposes to acquire the majority of the shares of Ranbaxy Laboratories Limited, India (“Ranbaxy”), for Indian Rupees 737 per share. Both parties are active worldwide in the pharmaceutical business. The total value of the transaction is expected to be between US\$ 3.4 and US\$ 4.6 billion. The proposed transaction falls within the scope of Council Regulation (EC) No. 139/2004.”